BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 14555506)

  • 1. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
    Lara PN; Frankel P; Mack PC; Gumerlock PH; Galvin I; Martel CL; Longmate J; Doroshow JH; Lenz HJ; Lau DH; Gandara DR
    Clin Cancer Res; 2003 Oct; 9(12):4356-62. PubMed ID: 14555506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
    Williamson SK; Crowley JJ; Lara PN; McCoy J; Lau DH; Tucker RW; Mills GM; Gandara DR;
    J Clin Oncol; 2005 Dec; 23(36):9097-104. PubMed ID: 16361616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
    Downs LS; Judson PL; Argenta PA; Carson LF; Boente MP
    Gynecol Oncol; 2004 Nov; 95(2):347-51. PubMed ID: 15491756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.
    Harries M; O'Donnell A; Scurr M; Reade S; Cole C; Judson I; Greystoke A; Twelves C; Kaye S
    Br J Cancer; 2004 Nov; 91(9):1651-5. PubMed ID: 15494716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
    Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
    J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.
    Hirabayashi M; Endoh K; Teramachi M; Okuda M; Yamaguchi K; Fukuda K; Tokuhisa H; Kagioka H; Nakai N; Nakade M
    Lung Cancer; 2004 Jun; 44(3):355-62. PubMed ID: 15140549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors.
    Creaven PJ; Raghavan D; Perez RP; Pendyala L; Berghorn EJ; Loewen G; Meropol NJ
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):26-31. PubMed ID: 9007117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
    Kobayashi H; Eckhardt SG; Lockridge JA; Rothenberg ML; Sandler AB; O'Bryant CL; Cooper W; Holden SN; Aitchison RD; Usman N; Wolin M; Basche ML
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):329-36. PubMed ID: 15906031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
    Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
    Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
    Fabi A; Barduagni M; Ferraresi V; Cortesi E; Gamucci T; De Marinis F; Saltarelli R; Gabriele A; Pellicciotta M; Ceribelli A; De Marco S; Facciolo F; Cognetti F
    J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
    Nemunaitis J; Cunningham C; Senzer N; Gray M; Oldham F; Pippen J; Mennel R; Eisenfeld A
    Cancer Invest; 2005; 23(8):671-6. PubMed ID: 16377585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
    Yoh K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Saijo N; Nishiwaki Y
    Lung Cancer; 2007 Oct; 58(1):73-9. PubMed ID: 17548127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.